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Angiotensinogen: Hormonal regulation and relative importance in the
generation of angiotensin II. The production of angiotensinogen is
controlled mainly by hormones that affect the concentration of its mRNA
in tissues. Accordingly, hormones that act upon gene transcription play a
prominent role. However, other factors may modulate the transcriptional
effects of hormones, and these should be considered to appreciate the final
effects of hormones on the secretion of angiotensinogen. The most
important role played by hormones in the regulation of angiotensinogen
may be to maintain its production in the face of rapid consumption by high
levels of renin. However, elevated levels of angiotensinogen may become
a risk factor in situations where the normal feedback regulation of renin
does not operate normally. Finally, the synthesis of angiotensinogen in
tissues may be regulated differentially than that in liver, although the exact
importance of these observations is still poorly understood.
Angiotensin II (Ang II) is a vasoactive peptide that plays
important roles in the control of blood pressure and in the
pathogenesis of a variety of cardiovascular diseases, including
hypertension, cardiac hypertrophy and cellular proliferation after
myointimal injury. The two factors that limit the rate of produc-
tion of Ang II are: (1) angiotensinogen (AUG), the glycoprotein
precursor to angiotensins, and (2) renin, the enzyme that pro-
cesses AOG. All available evidence indicates that AOG is se-
creted only constitutively and cannot be stored within secretory
granules [1]. This implies that the production of AOG is con-
trolled mostly at the level of synthesis, instead of secretion. In
agreement with this requirement, the hepatic production of AUG
is affected primarily by hormones that act at the genomic level,
that is, steroids and thyroid hormones. However, other factors
may affect how hormones act upon the AOG gene.
Endocrine regulation of liver angiotensinogen
Glucocorticoids (GC) are arguably the regulators of liver AOG
that have been studied in greatest detail. They greatly increase the
abundance of AOG mRNA both in liver (when administered in
vivo to experimental rodents) and in hepatoma cell lines (when
administered in vitro) [2]. Several studies have shown that this
effect is the consequence of an increase in transcription of the
AOG gene [3]. However, we have observed that GC had much
smaller effects on AUG secretion than on AUG mRNA concen-
tration, both in vivo and in vitro [21. This observation suggests that
GC, despite their strong effect on transcription of the AUG gene,
may have opposite effects on translation of its mRNA. In addition,
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most previous studies testing the effects of GC in vivo have used
doses that were about 100 times higher than that which is required
to induce hypercorticism. We have verified that chronic adminis-
tration of corticosterone at doses that (although moderate) in-
duced clear signs of hypercorticism did not stimulate plasma
AOG. These data make it unlikely that GC will serve as primary
regulators of AOG. Rather, their main function may be to serve as
permissive factors for the actions of other agents such as inter-
leukins [4].
Liver AUG production has been shown to be controlled by
estrogens and thyroid hormones as well. In contrast to glucocor-
ticoids, these two types of hormones affect both AOG secretion
and liver AUG mRNA concentration to a comparable extent.
However, other factors appear to be important in determining the
importance of their overall effect. For instance, the effect of
estrogens on liver AUG production was greater in female than in
male rats [5]. Likewise, estrogens did not stimulate liver AUG in
hypophysectomized rats, but responsiveness was restored by pre-
treating these animals with prolactin. These data indicate that
pituitary hormones may control the responsiveness of liver AUG
to estrogens by controlling the abundance of estrogen receptors in
liver cells.
The mechanism by which GC and estrogens increase transcrip-
tion of the AOG gene appears to derive from a direct interaction
between the 5'-flanking region of the gene and the DNA-binding
domains of their cognate receptors. In contrast, the action of
thyroid hormones appears to be dependent on the induction of
secondary genes, since their effect on AOG mRNA on hepatoma
cells in blocked by cycloheximide, a blocker of protein synthesis
[3]. This mechanism may explain why thyroid hormones induce
AOG secretion in subconfluent hepatoma cells but not in conflu-
ent cultures, whereas no differences in the abundance of thyroid
hormone receptors could be detected in these two types of
cultures [6]. Finally, some hormones might affect AOG mRNA
concentration without affecting gene transcription. Thus, it has
been shown recently that Ang II increases the synthesis of AOG
in hepatocytes by stabilizing its mRNA transcript [7]. This effect
results from an inhibition of ribonucleases following an Ang
Il-mediated decrease in intracellular cAMP.
These data indicate that, despite its the central role, gene
transcription is not the only factor that will determine the
response of AOG-secreting cells to a given hormone. This com-
plex interplay of hormones in the regulation of AUG mRNA is
summarized in Figure 1.
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Fig. 1. Schematic representation summarizing the effects of various hormones on the production of angiotensinogen by a liver cell. The effects of hormones
are represented by arrows, accompanied by the +, — or sign to indicate the nature of the effect. The ? sign means that the effect is still speculative.
Abbreviations are: AOG, angiotensinogen; T3, triiodothyronine; E2, estradiol; GC, glucocorticoids; IL, interleukins; -R, receptor; pit. horm., pituitary
hormones; prot, protein; CHX, cycloheximide; cAMP, cyclic adenosine monophosphate.
Pathophysiological importance of AOG regulation
The importance of maintaining adequate levels of AOG is
underscored by the fact that its concentration in circulating
plasma is close to the Km of the proteolytic activity of renin. As a
consequence, the amounts of Arig I generated by a fixed amount
of renin are directly proportional to the amounts of available
substrate. However, changes in plasma AUG are usually accom-
panied by inversely proportional changes in renin secretion. It
follows that hormonally-induced changes in plasma AUG are
usually not accompanied by any change in plasma renin activity or
Ang II concentration. In addition, it take several hours before
obtaining increases in AUG secretion following stimulation by
hormones that act at the genomic level. Because of these idiosyn-
crasies, it has been hard to pinpoint how exactly changes in the
levels of plasma angiotensinogen could affect blood pressure
and/or Ang II generation. Nevertheless, blood pressure is in-
creased in people who have genetic elevations in plasma AUG [8]
or in transgenic mice carrying the AUG gene [9]. Thus, it is
important to gain insights about how exactly AOG could affect
blood pressure.
To understand the role of AUG, it is important to keep in mind
that hypertension is a disease, and that it develops in a back-
ground that might be different from that of a healthy individual. In
particular, one should consider the consequence of changes of
plasma AUG when the normal feedback mechanism on renin
secretion does not function normally. This particular question has
been investigated recently by i.E. Sealey and collaborators. This
group had previously demonstrated that in Dahl salt-sensitive rats,
there was a paradoxical increase in renin secretion after six weeks
of salt-loading which appeared to be secondary to the appearance
of renal vascular lesions [10]. In those animals where renin was
paradoxically elevated (and apparently not under normal control),
there was a strong correlation between blood pressure and plasma
angiotensinogen, but no correlation with plasma renin concentra-
tion [11]. These data provide a framework to understand the
possible link that exists between angiotensinogen and blood
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pressure. Angiotensinogen is not a primary determinant in the
control of plasma Ang II, but may amplify the consequences of an
alteration of the normal regulatory mechanisms of renin secre-
tion. In that sense, it may literally function as a "risk factor." A
similar mechanism may explain why hypertension develops in
certain women undergoing estrogen therapy.
In nonhypertensive individuals, the role of regulators of AOG is
not to induce primary elevations, but to maintain its production in
the face of rapid consumption. Thus, important elevations in renin
induce a proportional depletion in AOG, which impairs the ability
of renin to generate angiotensins. One such situation is hemor-
rhage, where a stimulation of AUG has been shown to be essential
in order to allow renin to mount an efficient response [12]. In this
context, it is fitting that Ang II can stimulate AOG, since it is the
only hormone that can act in a relatively short period of time.
Other hormones (including interleukins and GC) will contribute
to sustain the response over extended periods of time.
Tissue angiotensinogen
Lastly, AUG is produced in many other tissues but liver,
including brain, adipose tissue and kidney. We have examined the
effects of various hormones on at least one of these tissues, the
brain. Diencephalon AUG mRNA concentration was significantly
decreased after adrenalectomy, but increased only marginally
after acute administration of dexamethasone [13]. Similarly, dien-
cephalon AOG mRNA concentration was decreased in hypothy-
roid rats, but did not increase in hyperthyroid rats [6]. Thus, the
main contributions of GC and thyroid hormones to the synthesis
of AOG in the brain appear to be confined to the maintenance of
basal levels of production. The effect of estrogens was more
variable. Thus, the amplitude, direction and time course of their
effect differed greatly between brain regions, indicating that
cell-specific factors modulated the effect of these hormones in
brain cells [5]. All together, these data indicate that regulation of
the AOG gene in extrahepatic tissues may be different from that
in the liver.
Conceivably, the production of AUG in tissues may be one
factor fostering the local production of angiotensins, especially if
(in contrast to kidney renin) there is no negative feedback
mechanism of Ang II on the production of renin (or renin-like
enzymes) in tissues. However, there is still no convincing evidence
to date demonstrating that alterations in the local concentration
of AUG in tissues induce corresponding changes in the local
concentration of Ang H. Before such data are available, it will be
hard to interpret the significance of regulation of angiotensinogen
in tissues. This difficulty is compounded by the fact that it is still
not clear how AOG can be converted into Ang II in tissues. This
is particularly puzzling in at least three cell-types where Ang II has
been located within secretory granules: in the kidney juxtaglomer-
ular cells, in the pituitary gonadotrophs and in nerve terminals.
Indeed, we have shown that AOG cannot be routed from the
Golgi to secretory granules [1], so the presence of Ang II within
the same secretory granules remains a mystery. One possibility is
that these cells internalize AUG from the surrounding extracel-
lular fluid. We are currently conducting experiments to test
whether such a mechanism could explain the presence of Ang II
within granules of the juxtaglomerular cells.
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